A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT)
TL;DR: It is concluded that IL-2 immunotherapy induces major salivary gland dysfunction in humans, similar to previous observations in patients with chronic GVHD, which may indicate similar pathophysiologic mechanisms.
Journal ArticleDOI
SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Maya Koren-Michowitz,Maya Koren-Michowitz,Sigal Gery,Takayuki Tabayashi,De-Chen Lin,Rocio Alvarez,Arnon Nagler,H. Phillip Koeffler,H. Phillip Koeffler +8 more
TL;DR: The data suggest that the loss of SH2B3 inhibitory function conferred by the PH domain mutations is mild and may collaborate with JAK2 V617F and CBL mutations in order to promote either the development or the progression of myeloproliferative neoplasms.
Journal ArticleDOI
Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.
Avichai Shimoni,Arnon Nagler +1 more
TL;DR: Preliminary results are promising and suggest improved disease control with no added toxicity; however randomized studies are needed to confirm these initial observations.
Journal ArticleDOI
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis
Vipul Sheth,Myriam Labopin,Jonathan Canaani,Liisa Volin,Arne Brecht,Arnold Ganser,Jiri Mayer,Hélène Labussière-Wallet,Jörg Thomas Bittenbring,Roni Shouval,Bipin N. Savani,Mohammad Mohty,Arnon Nagler +12 more
TL;DR: Overall survival, non-relapse mortality, and chronic GVHD were not significantly impacted by the specific regimen used, and the choice of either FLAMSA/TBI, FLamSA/Bu, or Treo/Flu results in no major impact on survival of older AML patients.
Journal ArticleDOI
Lba28carfilzomib (k) vs low-dose corticosteroids and optional cyclophosphamide (cy) in patients (pts) with relapsed and refractory multiple myeloma (rrmm): results from a phase 3 study (focus)
Heinz Ludwig,Tamás Masszi,M.T. Petrucci,Antonio Palumbo,Laura Rosiñol,Arnon Nagler,Kwee Yong,Jiri Minarik,Meletios-Athanasios Dimopoulos,Vladimir Maisnar,Davide Rossi,H. Kasparu,Dina Ben-Yehuda,Izhar Hardan,Matthew W Jenner,Kanya Rajangam,J F San Miguel,Roman Hájek +17 more
TL;DR: The study did not meet the primary endpoint for OS, but median OS for single-agent K (10.2 mo) was similar to the active control arm (10 mo) in these heavily pretreated pts with RRMM.